ES3065261T3 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof - Google Patents
Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereofInfo
- Publication number
- ES3065261T3 ES3065261T3 ES20862121T ES20862121T ES3065261T3 ES 3065261 T3 ES3065261 T3 ES 3065261T3 ES 20862121 T ES20862121 T ES 20862121T ES 20862121 T ES20862121 T ES 20862121T ES 3065261 T3 ES3065261 T3 ES 3065261T3
- Authority
- ES
- Spain
- Prior art keywords
- crystalline form
- pyridin
- compound
- cancer
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898469P | 2019-09-10 | 2019-09-10 | |
| PCT/US2020/049986 WO2021050580A1 (en) | 2019-09-10 | 2020-09-09 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3065261T3 true ES3065261T3 (en) | 2026-05-05 |
Family
ID=74866002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20862121T Active ES3065261T3 (en) | 2019-09-10 | 2020-09-09 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12466838B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4027999B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022546861A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114401720A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150267A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3065261T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021050580A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302597A (zh) * | 2021-03-10 | 2023-01-16 | 美商米拉蒂醫療公司 | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 |
| WO2022240802A1 (en) | 2021-05-10 | 2022-11-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of sitravatinib salts and processes for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103951583B (zh) | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| EP2183254B1 (en) * | 2007-08-29 | 2017-06-21 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2009026720A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| CN107646030A (zh) * | 2015-08-19 | 2018-01-30 | 桑多斯股份公司 | 丙二酸酯衍生物的不对称双酰胺化 |
| EP3740491A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN109384799B (zh) * | 2018-11-12 | 2020-07-14 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物 |
-
2020
- 2020-09-09 WO PCT/US2020/049986 patent/WO2021050580A1/en not_active Ceased
- 2020-09-09 CN CN202080063504.1A patent/CN114401720A/zh active Pending
- 2020-09-09 US US17/762,713 patent/US12466838B2/en active Active
- 2020-09-09 JP JP2022515704A patent/JP2022546861A/ja active Pending
- 2020-09-09 EP EP20862121.9A patent/EP4027999B1/en active Active
- 2020-09-09 ES ES20862121T patent/ES3065261T3/es active Active
- 2020-09-09 CA CA3150267A patent/CA3150267A1/en active Pending
-
2025
- 2025-04-03 JP JP2025061710A patent/JP2025102940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3150267A1 (en) | 2021-03-18 |
| JP2025102940A (ja) | 2025-07-08 |
| US20220402936A1 (en) | 2022-12-22 |
| JP2022546861A (ja) | 2022-11-09 |
| EP4027999A4 (en) | 2023-08-16 |
| WO2021050580A1 (en) | 2021-03-18 |
| EP4027999A1 (en) | 2022-07-20 |
| EP4027999C0 (en) | 2026-03-04 |
| CN114401720A (zh) | 2022-04-26 |
| US12466838B2 (en) | 2025-11-11 |
| EP4027999B1 (en) | 2026-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290106B1 (en) | Crystalline form of ATR inhibitor and its use | |
| IL274027A (en) | B-RAF kinase inhibitor salt crystals | |
| PL3915989T3 (pl) | Inhibitor jak i sposób jego otrzymywania | |
| IL288062A (en) | Crystalline forms of tapamidis and its salts | |
| EP3283486A4 (en) | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
| PT3894012T (pt) | Formas cristalinas e formas salinas de um inibidor de cinase | |
| EP3372607A4 (en) | Crystalline form of btk kinase inhibitor and preparation method thereof | |
| EP3216790A4 (en) | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL267393A (en) | Crystal forms of a Janus kinase inhibitor | |
| GB202101909D0 (en) | Novel crystalline form of pyroxa-sulfone, methods for its preparation and use of the same | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL289453A (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| ZA202107810B (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| EP3255046A4 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
| EP3677575A4 (en) | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR | |
| ZA202200964B (en) | Salts of a compound, crystal forms of the salts and preparation method and use thereof | |
| EP3530650A4 (en) | CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF | |
| EP4027999C0 (en) | CRYSTALLINE FORM OF A MULTIPLE TYROSINE KINASE INHIBITOR, ITS PREPARATION PROCESS AND ITS USE | |
| GB201918391D0 (en) | Novel crystalline forms of flufenacet, methods for their preparation and use of the same | |
| GB201918401D0 (en) | Novel crystalline forms of Flufenacet, methods for their preparation and use of the same | |
| PL3553060T3 (pl) | Polikrystaliczny mesylan inhibitora fosfodiesterazy typu 5, sposób jego przygotowania i jego zastosowanie | |
| SG11202111558VA (en) | Crystalline form of compound, method for preparing the same, pharmaceutical composition and use | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| EP3699177A4 (en) | METHOD OF MANUFACTURING A TYROSINKINAS INHIBITOR AND INTERMEDIATE THEREOF |